Share on LinkedInShare on LinkedIn

ARTICLE · 04 APRIL 2025

Patents And Drug Pricing

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

The price of branded drugs in the United States has been and continues to be a hot topic. While various causes have been alleged, recent attention has focused heavily on the U.S. patent system.

United StatesIntellectual Property

Why Weakening Patent Protection Is Not in the Public's Best Interest

The price of branded drugs in the United States has been and continues to be a hot topic. While various causes have been alleged, recent attention has focused heavily on the U.S. patent system. Lawmakers, the U.S. Patent and Trademark Office (USPTO), and even the former president have called for or sought to push through substantial changes to the patent system that weaken pharmaceutical patents. Blaming the patent system, however, overstates the impact patents have on drug prices. The correlation between the number of pharmaceutical patents associated with a product and competition is far from clear (as even the USPTO has found1 ), and by many metrics the patent system is working as intended. Yet many proposed "solutions" have treated patents as an easy fix without considering downstream ramifications.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from